Long-COVID Cardiomyopathy Probability Index (LCCPI) Calculator

Clinical calculation support · Verify results before clinical use

Clinical inputs

Select the findings documented during the acute COVID-19 episode. All four fields are required.

— Prototype score

Acute COVID-19 care setting

Highest level of care during the index infection.

Peripheral vascular disease (PVD)

Select yes if PVD is documented in the clinical history.

Type 2 diabetes mellitus

Select yes if type 2 diabetes is present.

Acute myocardial injury during index infection

Troponin above the assay upper reference limit and/or adjudicated myocarditis during acute COVID-19.

Important validation notice: LCCPI has no established peer-reviewed validation or calibrated probability model identified for this implementation. The point weights and score bands are retained from the supplied prototype and should be treated as exploratory only—not as a diagnosis, a rule-out tool, or a stand-alone basis for investigations or management.

About this prototype

This calculator adds four clinical features to produce a simple point total. It does not calculate absolute probability, establish cardiomyopathy, or replace an assessment of persistent or new cardiovascular symptoms after SARS-CoV-2 infection.

Original point weights retained

VariableInput categoryPoints
Acute care settingOutpatient / non-ICU inpatient / ICU0 / 2 / 3
Peripheral vascular diseaseNo / Yes0 / 2
Type 2 diabetesNo / Yes0 / 1
Acute myocardial injuryNo / Yes0 / 3

Original score bands (not validated)

TotalOriginal bandEvidence status
0–1LowCutoff not validated
2–4IntermediateCutoff not validated
5–9HighCutoff not validated

Clinical evaluation

For patients with persistent cardiopulmonary symptoms or findings suggestive of cardiac involvement, clinical assessment may include history and examination, ECG, cardiac troponin and echocardiography, with additional tests guided by presentation. CMR may be appropriate when myocardial involvement is suspected and the patient is clinically stable. Do not delay urgent evaluation because of a low prototype score.

Evidence and references

Xie Y, Xu E, Bowe B, Al-Aly Z.Long-term cardiovascular outcomes of COVID-19. Nature Medicine. 2022;28:583–590. Supports an association between COVID-19 and a range of post-acute cardiovascular outcomes, with graded risk by acute-care setting; it does not validate LCCPI weights or cutoffs. DOI: 10.1038/s41591-022-01689-3 · PubMed
Gluckman TJ, Bhave NM, Allen LA, et al.2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults. Journal of the American College of Cardiology. 2022. Provides a clinical framework for evaluating suspected myocardial involvement and persistent cardiovascular symptoms after COVID-19; it does not endorse this score. DOI: 10.1016/j.jacc.2022.02.003 · Full text
Clinical disclaimer: This prototype is for educational and exploratory use only. It is not a validated clinical prediction rule and must not be used to estimate an individual patient's probability of cardiomyopathy, exclude disease, or independently determine testing, treatment, admission, or follow-up. Evaluate red-flag symptoms—such as syncope, sustained ventricular arrhythmia, hemodynamic instability, heart-failure signs, or elevated cardiac biomarkers—promptly regardless of the score.